Level Zero Health, a female-founded medical device startup, has raised $6.9 million in pre-seed funding to develop a wearable device for continuous hormone monitoring. The investment round, led by European VC firm Redalpine, included contributions from HAX (SOSV), Entrepreneur First, and several industry experts.
Hormones play a crucial role in regulating bodily functions, yet conventional testing methods rely on invasive blood draws that only provide a snapshot in time. Level Zero Health aims to change this paradigm by creating a real-time monitoring solution using DNA-based sensors to measure hormone levels in interstitial fluid. This breakthrough could provide deeper insights into hormone-related conditions and pave the way for personalized healthcare innovations.
Bringing an entirely new medical device to market is no small feat, especially in the highly regulated healthcare industry. To accelerate entry, the company is following a dual-track product development strategy:
Level Zero Health’s ultimate goal is to establish a new market category—one that fosters new research, healthcare applications, and potential business opportunities built on real-time hormone data.
The company’s prototype wearable has already demonstrated promising results, with efforts focused on achieving a 90%+ correlation between interstitial fluid readings and traditional blood tests. Clinical trials are underway, and the team aims to secure regulatory clearance in both the U.S. (FDA) and Europe (CE Marking) by next year.
Unlike glucose monitoring, where delays in readings could have critical medical consequences, hormone monitoring carries a lower risk profile. This makes the technology easier to integrate into clinical practice without disrupting established protocols.
While Level Zero Health is initially targeting B2B healthcare providers, the potential applications extend far beyond clinical settings. The technology could revolutionize areas like:
The company’s long-term vision includes B2C expansion and partnerships with pharmaceutical firms, aiming to establish the world’s largest hormone health dataset to advance research and precision medicine.
Level Zero Health’s ambitious mission has attracted strong investor interest despite the challenging funding climate. The startup has assembled an impressive clinical advisory board, featuring top medical experts such as:
Philip Kneis, an investor at Redalpine and board member of Level Zero Health, remarked: “We did it for blood pressure and will do it again for hormones. Continuous hormone measurement is one of the holy grails of diagnostics, and as fundamental science transitions to engineering, we couldn’t be more excited to back Level Zero Health in their mission to transform hormone tracking with their novel biosensor – paving the way for a new era of personalized health management.”
With its cutting-edge biosensor technology, Level Zero Health is poised to redefine how hormone levels are tracked, analyzed, and applied in medicine. The journey from concept to market is still in progress, but the company’s recent funding and scientific advancements signal a promising shift in hormone-related healthcare. As research progresses and clinical trials yield more data, this technology could open doors to more personalized, accessible, and efficient hormone management solutions.
